Summary
Twenty-one patients suffering from different autoimmune diseases (14 from systemic lupus erythematosus, 4 from rheumatoid arthritis, one from Sjögren's syndrome, one from systemic hypersensitivity vasculitis, and one from diffuse proliferative glomerulonephritis) were treated with a combined immuno-suppressive regimen. Cyclosporin was given at a dose of 5 mg/kg/day together with steroids. In addition, the rheumatoid arthritis patients also received methotrexate. In all patients a kidney biopsy was performed after a treatment period of 17 to 42 months (mean duration 21.7 months). The cumulative cyclosporin dose at the time of biopsy varied from 1.071 to 4.587 mg/kg. Patients suffering from systemic lupus erythematosus and rheumatoid arthritis were assessed according to a scoring system set up for this purpose. The combined therapy proved useful in these patients as reflected in the diminution of the respective activity scores, improvement of kidney function, and diminution of proteinuria. Histological examination of the kidney biopsy specimens showed only minimal activity in patients with systemic lupus erythematosus. No unequivocal signs of renal toxicity could be detected. In the last group, the condition of the patient with Sjögren's syndrome was stabilized and the patient with systemic vasculitis improved clinically. Neither patient had signs of kidney lesions. The patient with diffuse proliferative glomerulonephritis, in whom kidney biopsy was performed before and after treatment, showed improvement of kidney function, diminution of proteinuria, and diminution of inflammatory activity within the kidney, and no signs of cyclosporin toxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- CyA:
-
Cyclosporin
- MTX:
-
Methotrexate
- NSAID:
-
Nonsteroidal antiinflammatory drugs
- RA:
-
Rheumatoid arthritis
- SLE:
-
Systemic lupus erythematosus
- TFA index:
-
Index of extent of tubular atrophy, intersitital fibrosis, and arteriolopathy
References
Austin HA, Muenz LR, Joyce KM, Antonovych TT, Balow JE (1984) Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 25:698–695
Bennett WM, Pulliam JP (1983) Cyclosporin nephrotoxicity. Ann Intern Med 99:851–854
Berg KJ, Forre O, Bjerkhoel F, Amundsen E, Djoseland O, Rugstad HE, Westre B (1986) Side effects of cyclosporin A treatment in patients with rheumatoid arthritis. Kidney Int 29:1180–1187
Beris Ph, Burger A, Favre L, Riondel A, Miescher PA (1986) Adrenocortical responsiveness after discontinous corticosteroid therapy. Klin Wochenschr 64:70–75
Boitnott JK, Solez K (1984) The use of ranking in the statistical assessment of morphological data. In: Solez K, Whelton A (eds) Acute renal failure. Marcel Dekker, New York/Basle
Churg J, Sobin LH (1982) Renal disease. Classification and atlas of glomerular diseases. Igaku-Shoin, Tokyo, New York, pp 127–131
Favre H (1973) Détermination des fonctions rénales par la technique de l'injection unique. Analyse statistique de modèle bicompartimental proposé par Sapirstein. J Urol Nephrol 79:1007–1052
Favre H, Miescher PA (1984) Filtration fraction: an index of the renal disease activity in SLE patients. Davison AM, Guillon PJ (eds) Proc EDTA 21. Pitman, Bath, England 717–721
Izui S, Lambert PH, Miescher PA (1976) Determination of anti-DNA antibodies by a modified125I-labelled DNA-binding test. Elimination of non-specific binding of DNA to non-immunoglobulin basic proteins by using an anionic detergent. Clin Exp Immunol 26:423–430
Miescher PA (1986) Treatment of systemic lupus erythematosus. Springer Semin Immunopathol 9:271–282
Miescher PA (1986) 20 years of methotrexate in the treatment of autoimmune diseases. Rheumatology 9:46–50
Mihatsch MJ, Thiel G, Ryffel B (1985) Cyclosporin-associated nephropathy. In: Schindler R (ed) Cyclosporin in Autoimmune Diseases. 1st International Symposium, Basel. Springer-Verlag, Berlin, Heidelberg, pp 50–58
Mihatsch MJ, Bohman SO, von Graffenried B, Harrison WB (1986) First Interim Report of Renal Biopsy Registry of Patients with Autoimmune Diseases Treated with Cyclosporin, in press
Myers BD, Ross J, Newton L, Leutscher J, Perlroth M (1984) Cyclosporin-associated chronic nephropathy. N Engl J Med 311:699–705
Nydegger UE, Achermann LM, Lambert PH, Miescher PA (1972) A simple automated method for complement estimation in a continuous flow system: J Immunol 109:910–913
Palestine AG, Austin HA, Balow JE, Antonovych TT, Sabnis SG, Preuss HG, Nussenblatt RB (1986) Renal histopathologic alterations in patients treated with cyclosporin for uveitis. N Engl J Med 314:1293–1297
Perrin LH, Lambert PH, Miescher PA (1975) Complement breakdown products in plasma from patients with membranoproliferative or other glomerulonephritis. J Clin Invest 56:165–176
Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, Buchanan WW (1968) Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 37:393–406 (1968)
Schindler R (ed) (1985) Cyclosporin in autoimmune diseases. Springer-Verlag, Berlin, Heidelberg
Svenson K, Bohman S-O, Hallgren R (1986) Renal interstitial fibrosis and vascular changes: occurrence in patients with autoimmune diseases treated with cyclosporin. Arch Intern Med 146:2007–2010
Zubler RH, Lange G, Lambert PH, Miescher PA (1976) Detection of immune complexes in unheated sera by a modified125I-C1q binding test. Effect of heating on the binding of C1q by immune complexes and application of the test to systemic lupus erythematosus. J Immunol 116:232–235
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Miescher, P.A., Favre, H., Chatelanat, F. et al. Combined steroid-cyclosporin treatment of chronic autoimmune diseases. Klin Wochenschr 65, 727–736 (1987). https://doi.org/10.1007/BF01736809
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01736809